NYSE:ATRPackaging
How Investors Are Reacting To AptarGroup (ATR) Landing Its First Dual Bidose Cardiovascular Nasal Product
AptarGroup recently announced that its Bidose Liquid Nasal Spray System is the delivery mechanism for Milestone Pharmaceuticals’ newly FDA-approved CARDAMYST (etripamil) nasal spray to convert acute episodes of paroxysmal supraventricular tachycardia to normal sinus rhythm in adults.
This marks AptarGroup’s first dual Bidose nasal delivery combination product, highlighting how its device platforms and regulatory services can support complex emergency-use therapies in cardiovascular...